Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anthony Weido

Allergy & Immunology Pasadena, TX Medical Doctor

NPI 1679570584 CMS profile 212068

6243 Fairmont Pkwy Ste 102, Pasadena, TX 77505

Open in the dashboard

General payments

$31,276

271 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anthony Weido of Pasadena, TX is reported in the CMS Open Payments database as having received $31,276 across 271 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,513 70
2024 General $878 37
2023 General $721 32
2022 General $560 28
2021 General $490 25
2020 General $300 1
2019 General $26,814 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anthony Weido
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Anthony Weido were reported at $1,513. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Anthony Weido Allergy & Immunology median Middle half National median
2019 $26,814 $594 $163–$1,512 $163
2020 $300 $426 $106–$1,233 $114
2021 $490 $638 $157–$1,708 $132
2022 $560 $790 $205–$1,961 $149
2023 $721 $852 $220–$2,147 $160
2024 $878 $865 $203–$2,267 $164
2025 $1,513 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $27,142 75 payments
  2. GlaxoSmithKline, LLC. $715 38 payments
  3. CSL Behring $576 25 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $519 20 payments
  5. Regeneron Healthcare Solutions, Inc. $240 11 payments
  6. kaleo, Inc. $229 11 payments
  7. Pfizer Inc. $194 11 payments
  8. Genentech USA, Inc. $163 3 payments
  9. Genzyme Corporation $145 7 payments
  10. Novartis Pharmaceuticals Corporation $145 7 payments
  11. Other $1,208 63 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $24,600 12 payments
  2. Food and Beverage $5,868 248 payments
  3. Travel and Lodging $734 8 payments
  4. Consulting Fee $60 2 payments
  5. Education $15 1 payment
Products named General payments · program years 2019–2025
  1. FASENRA Respiratory $26,335 37 payments
  2. TRELEGY ELLIPTA $456 25 payments
  3. CUVITRU $340 13 payments
  4. Hizentra $329 14 payments
  5. NUCALA $228 11 payments
  6. AIRSUPRA $226 10 payments
  7. Haegarda $211 9 payments
  8. FASENRA Respiratory $194 12 payments
  9. AUVI-Q $190 9 payments
  10. AREXVY $186 10 payments
  11. Other $2,979 145 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

88

Median for Allergy/ Immunology: 449

Drug cost

$29,706

Median for Allergy/ Immunology: $169,700

Branded share of claims

34.1%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 30 $28,623
Azelastine Hcl Generic 35 $807
Montelukast Sodium Generic 23 $276

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XOLAIR
  • Genentech USA, Inc. $114
  • Novartis Pharmaceuticals Corporation $24
$138 — —
CUVITRU
  • Takeda Pharmaceuticals U.S.A., Inc. $125
$125 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $79
$79 30 —
AYVAKIT
  • Blueprint Medicines Corporation $67
$67 — —
Haegarda
  • CSL Behring $61
$61 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

271 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record